CClinicalTrials.gg
CompletedNCT01566253Updated Apr 4, 2013

Oral Self Medication Versus IV Administration of Pain Killers After Caesarian Delivery

A Phase 4 interventional study of Acetaminophen, ketoprofen, morphine and Acetaminophen, ketoprofen,morphine in Caesarian Section, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to female participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2013-04-04.

Sponsored by University Hospital, Montpellier · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
Female
01

Study summary

C-section deliveries are painful and need adequate analgesia. In the same time, mothers need early rehabilitation to take care of the baby.

Hypothesis: Early oral self administration of painkillers could be as effective as usual IV administration by nursing staff.

Purpose of the study: Evaluation of the efficacy of a program of self administration of painkillers postoperatively of C-section delivery.

Read the detailed description

Two Arms: PCOA group receiving oral self administered multimodal analgesic protocol and IV group receiving same multimodal analgesic protocol administered by nursing staff.

02

Conditions studied

  • Caesarian Section

Keywords

  • planned caesarian section, analgesic, PCOA
03

In context

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • planned caesarian section

Exclusion criteria

Exclusion Criteria:

  • delivery bleeding which requires general anaesthetic and other surgical treatment
  • contraindication of the targetted anaesthetic because of hemostatis dysfunctionments
  • Signed consent form
  • under 18 years old, toxicomania
  • do not french speacking
  • allergia or contraindication to IMPs
  • suffer from chronicle disease
  • do not affiliate to a health protection
  • do not want to cooperate with the medical staff
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    PCOA

    The PCOA arm receiving oral self administered multimodal analgesic protocol (paracetamol, ketoprofen, morphine) by oral use.

    Drug: Acetaminophen, ketoprofen, morphine

  • Active comparator
    Standard/ IV

    The standard/IV arm will be received the analgesic treatment by intravenous use, administered by nursing staff.

    Drug: Acetaminophen, ketoprofen,morphine

Interventions

  • DrugAcetaminophen, ketoprofen, morphine

    Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours

    Also known as: dolipraneoro 500mg, MA 352 120-2, bi profenid LP 100 mg, MA 399804-5, Actiskenan 10 mg, MA 561958-9

  • DrugAcetaminophen, ketoprofen,morphine

    Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.

    Also known as: Paracetamol 1g/100 ml IV : MA #571860-1, Profenid IV : MA #557466-8, Morphine IV : MA #566945-2

06

What researchers measure

Primary outcomes

  1. Median pain score during the first 48 hours (Verbal rating PAin Scale)

    The pain score will be assessed by investigators at different times : H2 (2 hours after the end of the caesarian), H6, H12, H18, H24, H30, H36 and H48.

    Time frame: After 48 hours

Secondary outcomes

  1. Onset of the first request of rescue analgesic drug

    If the study analgesic treatment is not enough, a rescue analgesic drug could administered by nursing staff.

    Time frame: maximum 48 hours following the caesarian

07

Study locations

1 site
  • university Hospital, Arnaud de Villeneuve, Gynecology department
    Montpellier, 34295, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01566253
Lead sponsor
University Hospital, Montpellier
Collaborators
Club anesthésie Reanimation Obstetricale
Responsible party
Sponsor
First posted
Mar 29, 2012
Start date
Mar 2012
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Apr 4, 2013

Study contacts

Estelle Morau, Doctor
principal investigator · University Hosptial of Montpellier

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion